방법 비교

	GERD 건강 관련 삶의 질 척도	위마비 주요 증상 지수	환자 변비 삶의 질 평가	과민성 대장 증후군에 대한 Rome IV 진단 기준	단기 염증성 장질환 설문지
분야	소화기학	소화기학	소화기학	소화기학	소화기학
계열	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
기원 연도	1996	2003	2005	2016	2004
창시자	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Marquis, P., De La Loge, C., Dubois, D., et al.	Rome Foundation (multinational expert consensus)	Guyonnet, D., Chassany, O., Ducroc, R., et al.
유형	Self-report	Self-report	Self-report	Diagnostic Criteria	Self-report
원전	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005). Development and validation of the Patient Assessment of Constipation-Quality of Life questionnaire. Scandinavian Journal of Gastroenterology, 40(5), 540–551.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
별칭	GERD-HRQL, GERD-HRQoL	GCSI	PAC-QoL, PAC-Q	Rome IV IBS, Rome Criteria	IBDQ-32, Short IBDQ
관련	4	4	4	4	4
요약	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The Patient Assessment of Constipation Quality of Life (PAC-QoL) is a validated, patient-reported outcome measure designed to assess the impact of functional constipation on physical, psychological, and social well-being. Developed by Marquis and colleagues in 2005, the PAC-QoL comprises 28 items organized into four domains: Physical Discomfort, Psychosocial Discomfort, Worries and Concerns, and Satisfaction. The PAC-QoL is responsive to treatment and widely used in constipation clinical trials and practice.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.